Every material Form 8-K Medical Properties Trust filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medical Properties Trust reported a third-quarter 2025 net loss of $78 million ($0.13 per share), much narrower than the $801 million loss a year earlier, while normalized funds from operations (NFFO) fell to $77 million ($0.13 per share) from $94 million ($0.16). The board also approved a stock repurchase program of up to $150 million, which the company is under no obligation to use.
Third-quarter total revenues were $237.5 million, up from $225.8 million a year earlier.
Third-quarter NFFO was $77 million ($0.13 per share), down from $94 million ($0.16 per share) in the 2024 period.
The net loss includes about $82 million in impairment charges, primarily related to Prospect Medical Group bankruptcy transactions.
On October 28, 2025, the board approved a repurchase program for up to $150 million of common stock.
Medical Properties Trust reported a second-quarter 2025 net loss of $98 million ($0.16 per share), smaller than the $321 million ($0.54 per share) loss a year earlier. Normalized funds from operations (NFFO) fell to $81 million ($0.14 per share) from $139 million ($0.23 per share), and total revenues declined to $240.4 million from $266.6 million, so shareholders see a smaller loss alongside weaker operating measures.
Net loss of $98 million ($0.16 per share) for Q2 2025 vs. $321 million ($0.54 per share) in Q2 2024; the quarter includes about $111 million ($0.18 per share) in impairment and fair market value adjustments.
NFFO of $81 million ($0.14 per share) vs. $139 million ($0.23 per share) a year earlier; total revenues were $240.4 million vs. $266.6 million.
Cash rental income from new tenants rose to $11.0 million from $3.4 million in Q1 2025; scheduled third-quarter cash collections approximate $17 million.
A regular quarterly dividend of $0.08 per share was paid in July 2025.
Medical Properties Trust reported a first-quarter 2025 net loss of $118 million, or $0.20 per share, down from $876 million, or $1.46 per share, a year earlier. The company said the narrower loss reflects lower impairment charges, while total revenue fell to $224 million from $271 million and normalized FFO fell to $81 million, or $0.14 per share, from $142 million, or $0.24 per share.
Net loss attributable to common stockholders was $118 million ($0.20 per share), versus $876 million ($1.46 per share) in the first quarter of 2024.
Total revenues were $224 million, compared with $271 million a year earlier.
Normalized FFO was $81 million ($0.14 per share), compared with $142 million ($0.24 per share) a year earlier.
Net loss includes about $73 million ($0.12 per share) in impairments and fair value adjustments tied to Prospect Medical Group and PHP Holdings; a $0.08 per share dividend was paid in April.
Medical Properties Trust reported a fourth-quarter 2024 net loss of $413 million ($0.69 per share) and a full-year net loss of $2.4 billion ($4.02 per share), including about $415 million of impairments and fair market value adjustments tied to Prospect Medical Group and PHP Holdings. Normalized FFO fell to $0.18 per share for the quarter from $0.36 a year earlier and to $0.80 for the year from $1.59. The company said a $2.5 billion senior secured notes offering addresses all debt maturities through 2026.
Q4 2024 net loss of $413 million ($0.69 per share) versus $664 million ($1.11 per share) in Q4 2023
Q4 2024 normalized FFO of $0.18 per share versus $0.36; full-year 2024 normalized FFO of $0.80 versus $1.59
Full-year 2024 net loss of $2.4 billion ($4.02 per share) versus $556 million ($0.93 per share) in 2023
Private offering of more than $2.5 billion of senior secured notes due 2032 at a blended coupon of 7.885%
On February 13, 2025, MPT's operating partnership closed $1.5 billion of 8.500% notes due 2032 and €1.0 billion of 7.000% notes due 2032, and the company amended its revolving credit and term loan agreement. The notes are secured by first-priority liens on equity of subsidiaries owning or ground leasing 169 properties, and the amendment extends the revolving facility's maturity to June 30, 2027 while removing several financial covenants and resetting the interest rate to SOFR plus 2.25%. The filing shows new secured debt ranking alongside the credit facility, which may affect how much collateral is available to unsecured creditors and shareholders.
$1.5 billion of 8.500% Senior Secured Notes due February 15, 2032 and €1.0 billion of 7.000% Senior Secured Notes due 2032 were issued under an indenture dated February 13, 2025.
Notes are secured by first-priority liens on equity of subsidiaries that own or ground lease 169 properties with 20 operators in the United States, United Kingdom and Germany.
Amendment No. 3 extends the revolving credit facility maturity to June 30, 2027, resets interest to SOFR plus 2.25% and sets a maximum secured leverage ratio of 40%.
Before February 15, 2028, up to 40% of each note series may be redeemed at 108.500% (dollar notes) or 107.000% (euro notes) using equity offering proceeds.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medical Properties Trust filing is on SEC EDGAR ↗. 8-K briefs of other companies →